Latest Health News

CONNEQT Health reports robust sales momentum for its CONNEQT Pulse arterial health monitor, with quarterly sales growth exceeding 50% and a fresh order for 10,000 units to meet rising demand.

Nexsen Limited has initiated clinical trials for its StrepSure® GBS Rapid Sensor, a next-generation diagnostic device aimed at improving maternal health outcomes. The trial's success could pave the way for regulatory approval and early market penetration by the second half of 2026.

Genetic Signatures Ltd reports a robust start to FY2026 with a 20% quarterly sales increase, driven by new US contracts and strong growth in EMEA and Australia. The company also bolsters its leadership with a new CTO appointment.

Cleanaway Waste Management faced a challenging FY25 with multiple fatalities prompting a safety overhaul, yet reported robust financial growth and reaffirmed FY26 guidance. Strategic acquisitions and operational improvements signal a determined path forward.

Ramsay Health Care announces a fully franked ordinary distribution of AUD 2.9642 per security on its perpetual preference shares, reflecting a steady income stream for investors. The payment is scheduled for April 2026, subject to board and external approvals.

BCAL Diagnostics has launched a $10 million convertible note facility, with $5 million already committed, to strengthen its capital position and accelerate commercialisation of its cancer detection technologies.

PolyNovo Limited reported a robust 33.3% increase in Q1 FY26 sales, driven by strong U.S. growth and a remarkable surge in NovoSorb MTX sales. The company also completed key infrastructure projects, positioning itself for further expansion.

Singular Health Group has advanced its US expansion through the deployment of 3DICOM™ licenses under a key contract with Provider Network Solutions, alongside appointing a new US commercial chief to drive growth.

Race Oncology showcased compelling preclinical data at ESMO 2025 revealing that their drug RC220, combined with doxorubicin, not only shields the heart from toxicity but also boosts anticancer effects, supporting ongoing clinical trials.

DroneShield Limited has delivered a blockbuster quarter with record revenue and operating cash flow, driven by new SaaS products and major government contracts. The company is positioning itself for sustained profitability and expansion into civilian markets.

BCAL Diagnostics has established a $10 million convertible note facility, with $5 million already committed, to accelerate its cancer detection technologies and commercial milestones.

DGL Group Limited remains suspended from ASX trading following delays in lodging audited accounts and a concerning auditor disclaimer. Investors await clarity on the company’s financial health and path to reinstatement.